UY33758A - Acidos indaniloxidihidrobenzofuranilaceticos - Google Patents
Acidos indaniloxidihidrobenzofuranilaceticosInfo
- Publication number
- UY33758A UY33758A UY0001033758A UY33758A UY33758A UY 33758 A UY33758 A UY 33758A UY 0001033758 A UY0001033758 A UY 0001033758A UY 33758 A UY33758 A UY 33758A UY 33758 A UY33758 A UY 33758A
- Authority
- UY
- Uruguay
- Prior art keywords
- indaniloxidihidrobenzofuranilacetic
- acids
- compounds
- receptor
- diseases
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 abstract 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10193382 | 2010-12-01 | ||
| EP11154999 | 2011-02-18 | ||
| EP11175646 | 2011-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY33758A true UY33758A (es) | 2012-06-29 |
Family
ID=45063142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001033758A UY33758A (es) | 2010-12-01 | 2011-11-30 | Acidos indaniloxidihidrobenzofuranilaceticos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120302566A1 (enExample) |
| EP (1) | EP2646425B1 (enExample) |
| JP (1) | JP5853317B2 (enExample) |
| AR (1) | AR084050A1 (enExample) |
| DK (1) | DK2646425T3 (enExample) |
| ES (1) | ES2546154T3 (enExample) |
| HU (1) | HUE025363T2 (enExample) |
| PL (1) | PL2646425T3 (enExample) |
| UY (1) | UY33758A (enExample) |
| WO (1) | WO2012072691A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642585B2 (en) * | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| US8809376B2 (en) * | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| JP5913752B2 (ja) | 2012-11-28 | 2016-04-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規インダニルオキシジヒドロベンゾフラニル酢酸 |
| JP6283862B2 (ja) * | 2012-12-07 | 2018-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規インダニルオキシジヒドロベンゾフラニル酢酸 |
| WO2014122067A1 (en) | 2013-02-06 | 2014-08-14 | Boehringer Ingelheim International Gmbh | New indanyloxydihydrobenzofuranylacetic acids |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2015024526A1 (en) * | 2013-08-23 | 2015-02-26 | Fujian Haixi Pharmaceuticals Co., Ltd | Carboxylic acid compounds in treatment of diabetes mellitus |
| WO2015044073A1 (en) * | 2013-09-26 | 2015-04-02 | Boehringer Ingelheim International Gmbh | Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists |
| EP3068768B1 (en) | 2013-11-15 | 2019-07-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3074375B1 (en) * | 2013-11-28 | 2018-04-04 | Boehringer Ingelheim International GmbH | New indanyloxyphenylcyclopropanecarboxylic acids |
| US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| CN105001212B (zh) * | 2014-04-16 | 2018-01-16 | 江苏柯菲平医药股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3177285B1 (en) | 2014-08-08 | 2020-09-23 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3177282B1 (en) | 2014-08-08 | 2021-10-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| CN104177320B (zh) * | 2014-08-27 | 2016-03-02 | 广东东阳光药业有限公司 | 一种脲取代联苯类化合物及其组合物及用途 |
| WO2017172505A1 (en) | 2016-03-29 | 2017-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| KR102007633B1 (ko) * | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| WO2018138027A1 (en) | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof |
| WO2018138028A1 (en) | 2017-01-26 | 2018-08-02 | Boehringer Ingelheim International Gmbh | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| EP3573969A1 (en) | 2017-01-26 | 2019-12-04 | Boehringer Ingelheim International GmbH | Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| WO2018146008A1 (en) * | 2017-02-08 | 2018-08-16 | Boehringer Ingelheim International Gmbh | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
| US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| EP4359401A1 (en) * | 2021-06-23 | 2024-05-01 | Blueprint Medicines Corporation | Process for preparing egfr inhibitors |
| WO2025140655A1 (en) * | 2023-12-30 | 2025-07-03 | Fujian Haixi Pharmaceuticals Co., Ltd. | Heteroaryl compounds as multi-target protein kinase inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2628103B1 (fr) | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| EP1559422B1 (en) | 2002-11-08 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP1833858A2 (en) | 2004-12-16 | 2007-09-19 | Exxonmobil Chemical Patents Inc. | Halogen substituted metallocene compounds for olefin polymerization |
| WO2007033002A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| CA2647811A1 (en) * | 2006-03-30 | 2007-10-11 | Asahi Kasei Pharma Corporation | Substituted bicyclic derivative and use thereof |
| RS53230B (sr) | 2006-06-27 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora |
| US8039484B2 (en) * | 2006-10-31 | 2011-10-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| CN102076650A (zh) | 2008-06-25 | 2011-05-25 | 第一三共株式会社 | 羧酸化合物 |
| JP5551707B2 (ja) * | 2008-10-15 | 2014-07-16 | アムジエン・インコーポレーテツド | スピロ環ｇｐｒ４０調節因子 |
| JP5657578B2 (ja) * | 2009-06-09 | 2015-01-21 | 武田薬品工業株式会社 | 新規な縮合環化合物およびその用途 |
| US8642585B2 (en) * | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
-
2011
- 2011-11-30 US US13/307,455 patent/US20120302566A1/en not_active Abandoned
- 2011-11-30 DK DK11788845.3T patent/DK2646425T3/en active
- 2011-11-30 EP EP11788845.3A patent/EP2646425B1/en not_active Not-in-force
- 2011-11-30 UY UY0001033758A patent/UY33758A/es not_active Application Discontinuation
- 2011-11-30 ES ES11788845.3T patent/ES2546154T3/es active Active
- 2011-11-30 HU HUE11788845A patent/HUE025363T2/en unknown
- 2011-11-30 AR ARP110104457A patent/AR084050A1/es unknown
- 2011-11-30 WO PCT/EP2011/071410 patent/WO2012072691A1/en not_active Ceased
- 2011-11-30 JP JP2013541333A patent/JP5853317B2/ja not_active Expired - Fee Related
- 2011-11-30 PL PL11788845T patent/PL2646425T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE025363T2 (en) | 2016-02-29 |
| ES2546154T3 (es) | 2015-09-21 |
| JP5853317B2 (ja) | 2016-02-09 |
| US20120302566A1 (en) | 2012-11-29 |
| AR084050A1 (es) | 2013-04-17 |
| EP2646425A1 (en) | 2013-10-09 |
| EP2646425B1 (en) | 2015-06-10 |
| DK2646425T3 (en) | 2015-08-24 |
| WO2012072691A1 (en) | 2012-06-07 |
| JP2013544268A (ja) | 2013-12-12 |
| PL2646425T3 (pl) | 2015-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33758A (es) | Acidos indaniloxidihidrobenzofuranilaceticos | |
| ECSP14023238A (es) | Nuevos derivados de ácidos indaniloxidihidrobenzofuranilacéticos y sus usos como agonistas del receptor gpr40 | |
| ECSP13012900A (es) | Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos | |
| UY35156A (es) | Derivados del ácido indaniloxi dihidrobenzofuranil acético como agonistas de las gpr40 | |
| UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
| UY35171A (es) | Derivados de ácidos indaniloxidihidrobenzofuranilacéticos como agonistas de la gpr40 | |
| DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| NI200900148A (es) | COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33536A | |
| ECSP109906A (es) | Compuestos antivirales | |
| ECSP11011044A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
| CU20110030A7 (es) | Compuestos orgánicos | |
| MX2019003738A (es) | Compuestos antivirales. | |
| CO6511283A2 (es) | Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer | |
| CO7240375A2 (es) | Compuestos tricíclicos sustituidos como inhibidores del fgfr | |
| CR20140197A (es) | Compuestos con actividad nematicida | |
| DOP2017000013A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
| UY32778A (es) | Terapia de combinación para el tratamiento de la diabetes | |
| CR20110255A (es) | Nuevos compuestos 578 | |
| UY35312A (es) | Ácidos indaniloxidihidrobenzofuranilacéticos como agonistas del receptor acoplado a la proteína g40 | |
| UY31803A (es) | Compuesto cristalino | |
| UY35668A (es) | Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen | |
| CO6660462A2 (es) | Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos | |
| UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
| PA8793101A1 (es) | Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20200904 |